COVID-19 and lupus share a common immune misfiring pathway, new study finds

A new study published in Immunity has uncovered why some COVID-19 patients develop autoimmune complications after infection. Researchers from the Institute for Systems Biology (ISB) analyzed data from 209 COVID-infected participants and found that a specific subset of immune cells — called double-negative 2 (DN2) B cells — are significantly overrepresented in people who produce high levels of autoantibodies (proteins that mistakenly attack the body's own tissues).

DN2 cells have previously been linked to autoimmune diseases like lupus, and the new findings suggest that SARS-CoV-2 infection can activate the same immune program seen in established autoimmune disorders. This helps explain why certain individuals experience persistent symptoms or new-onset autoimmune disease following COVID-19.

Key Takeaways:

• DN2 B cells, a subtype of atypical memory B cells, were enriched in COVID patients with high autoantibody levels
• Innate sensing pathways were notably more active in the high-autoantibody group, particularly in DN2 cells
• These immune pathways could serve as future therapeutic targets to prevent post-infection autoimmune responses

Why it matters: Understanding the cellular and molecular mechanisms behind COVID-triggered autoimmunity brings researchers closer to developing interventions that could protect vulnerable patients — especially women and older adults — from long-term autoimmune complications after infection.